Similar trends were observed for changes in total cholesterol .
Implication sGiven the available data , the addition of ezetimibe to ongoing simvastatin , atorvastatin , or rosuvastatin monotherapy offers greater reduction in LDL-C among patients at high risk of CVD compared to doubling the initial statin dose
Purpose While statins are used as first-line treatments for high-risk patients with hypercholesterolemia , statin monotherapy is often insufficient to achieve target low-density lipoprotein cholesterol ( LDL-C ) levels .
Second-line treatment options include up-titration of statin dose , switching to a more potent statin , or combination therapy , e.g. , with ezetimibe .
The aim of this study was to evaluate the efficacy of adding ezetimibe to simvastatin , atorvastatin , or rosuvastatin monotherapy versus doubling the dosage or switching to a higher-potency statin in a population of patients with hypocholesterolemia at high risk of cardiovascular disease ( CVD ) and who had been previously treated with a statin .
Hypolipidaemic and anti-inflammatory effects of fixed dose combination of atorvastatin plus ezetimibe in Indian patients with dyslipidaemia.
INTRODUCTION We aim ed to assess the efficacy of fixed dose combination of atorvastatin plus ezetimibe in Indian patients with dyslipidaemia . METHODS A double-blind study was conducted to assess the effect of fixed dose combination of ezetimibe 10 mg plus atorvastatin 10 mg on lipid profile , oxidised low-density lipoprotein ( ox-LDL ) , high-sensitivity C-reactive protein ( hsCRP ) and soluble intercellular cell adhesion molecule ( sICAM ) in dyslipidaemic patients with or at high risk of coronary artery disease , and compare it with atorvastatin 10 mg monotherapy . 30 patients were r and omised to receive ezetimibe plus atorvastatin or atorvastatin once daily for four weeks . RESULTS Of the 30 patients , 10 men and 5 women ( mean age 54.3 ± 1.6 years ) received ezetimibe plus atorvastatin , while 13 men and 2 women ( mean age 53.7 ± 2.8 years ) received only atorvastatin . The combination treatment significantly reduced total cholesterol ( percentage treatment difference -14.4 ± 6.5 , 95 % confidence interval [ CI ] -1.0 to -27.7 ; p = 0.041 ) and LDL cholesterol ( LDL-C ; percentage treatment difference -19.9 ± 6.1 , 95 % CI -7.4 to -32.4 ; p = 0.003 ) compared to atorvastatin monotherapy . 13 patients on combination treament achieved the National Cholesterol Education Program target for LDL-C as compared to 9 patients  on atorvastatin monotherapy ( p = 0.032 ) . Significant reductions in very low-density lipoprotein cholesterol , triglyceride , ox-LDL and sICAM were observed with combination treatment compared to atorvastatin monotherapy . However , no significant change was seen in high-density lipoprotein cholesterol or hsCRP levels between the two groups . CONCLUSION Combination treatment with atorvastatin and ezetimibe had relatively better lipid-lowering and anti-inflammatory efficacy  than atorvastatin monotherapy
Similar trends were observed for changes in total cholesterol .
Implication sGiven the available data , the addition of ezetimibe to ongoing simvastatin , atorvastatin , or rosuvastatin monotherapy offers greater reduction in LDL-C among patients at high risk of CVD compared to doubling the initial statin dose
Purpose While statins are used as first-line treatments for high-risk patients with hypercholesterolemia , statin monotherapy is often insufficient to achieve target low-density lipoprotein cholesterol ( LDL-C ) levels .
Second-line treatment options include up-titration of statin dose , switching to a more potent statin , or combination therapy , e.g. , with ezetimibe .
The aim of this study was to evaluate the efficacy of adding ezetimibe to simvastatin , atorvastatin , or rosuvastatin monotherapy versus doubling the dosage or switching to a higher-potency statin in a population of patients with hypocholesterolemia at high risk of cardiovascular disease ( CVD ) and who had been previously treated with a statin .